In the pivotal clinical trials of intravenous tissue plasminogen activator (TPA) therapy, a low rate of early arterial recanalization was suspected because only a few stroke patients may have had early dramatic clinical improvement. Tissue plasminogen activator activity can be enhanced with ultrasound, including 2 MHz transcranial Doppler (TCD). Transcranial Doppler identifies residual blood flow signals around thrombi, and, by delivering mechanical pressure waves, exposes more thrombus surface to circulating TPA. For the first time in clinical medicine, the international multicenter CLOTBUST trial showed that ultrasound enhances the thrombolytic activity of a drug in humans, thereby confirming multidisciplinary experimental research conducted worldwide for the past 30 years. In the CLOTBUST trial, the dramatic clinical recovery from stroke coupled with complete recanalization within 2 h after TPA bolus occurred in 25% of patients treated with TPA1TCD compared with 8% who received TPA alone (P 5 0Á02). Complete clearance of a thrombus and dramatic recovery of brain functions during treatment are feasible goals for ultrasound-enhanced thrombolysis that can lead to sustained recovery. An early boost in brain perfusion seen in the target CLOTBUST group resulted in a trend of 13% more patients achieving favorable outcome at 3 months. To further enhance the ability of TPA to break up thrombi, current ongoing clinical trials include phase II studies of 2 MHz TCD with ultrasound contrast agents or (microbubbles): TCD1TPA1Levovist; TCD1TPA1MRX nano-platform (C 3 F 8 ). Intra-arterial TPA delivery can be enhanced with 1Á7-2Á1 MHz pulsed wave ultrasound (EKOS catheter, IMS trial). Dose escalation studies of microbubbles, ultrasound exposure, and the development of an operator-independent ultrasound device are underway.
Introduction
Unlike thrombolysis for myocardial ischemia, pilot clinical studies of thrombolysis for ischemic stroke did not document dramatic or 'on the table' clinical recovery during treatment (1) (2) (3) . Subsequent pivotal trials of TPA have not reported any differences between the groups at 2 and 24 h posttreatment in the prespecified end-points (4-7). However, a post hoc analysis of the NINDS trial (8) showed that by 24 h, 27% of TPA-treated patients improved by Z10 points on the National Institutes of Health Stroke Scale (NIHSS) or their neurological deficit completely resolved compared with 12% in the placebo group (P 5 0Á002). Therefore, some patients may have experienced early clinical recovery because of fast thrombus dissolution, but the overall number of these events was low.
Early clinical improvement after stroke usually occurs after arterial recanalization (9) (10) (11) (12) . Recanalization was measured in a pilot angiographic study of TPA therapy for stroke (1) but not in the NINDS rt-PA Stroke Study or European Cooperative Stroke Studies (4-7). As early recanalization can lead to dramatic recovery (9) (10) (11) (12) , any additional enhancement of TPA-associated thrombus dissolution, in theory, should produce even higher early recovery rates among patients with ischemic stroke.
The ability of a mechanical pressure wave, i.e. ultrasound, to enhance thrombolysis has been documented since the 1970s (13, 14) and confirmed by many in experimental models (15) (16) (17) (18) (19) . A simple analogy is that if you put sugar in a cup of water, sugar promptly goes down to the bottom, and it will take some time for it to dissolve completely because there is no water motion. If you stir water with a spoon, sugar dissolves much faster. In stroke, it takes a long time for TPA to get to the target owing to stagnant flow near the occlusion. Ultrasound, as its pressure wave propagates through tissues, induces fluid motion and helps TPA to reach the binding sites.
Although low kilohertz frequencies better potentiate TPA effects (20) , these systems are not available for clinical practice owing to safety concerns and inability to image vasculature with this frequency/wavelength range. Meanwhile, 1-2Á2 MHz frequencies can also enhance TPA-induced thrombus dissolution utilizing different mechanisms such as fluid streaming around the clot surface, disaggregation of fibrin fibers, and creating more binding sites for TPA without heating or cavitation (21, 22) . This frequency range is safely used for diagnostic ultrasound examinations.
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The CLOTBUST trial
The CLOTBUST (Combined Lysis of Thrombus in Brain ischemia using transcranial Ultrasound and Systemic TPA) was a phase II clinical randomized multicenter international trial with centers in Houston, Barcelona, Edmonton, and Calgary (25) . It had prespecified safety and signal of efficacy end-points and a predetermined sample size of 63 patients per group (25) . All enrolled patients had an acute ischemic stroke, and were treated with a standard 0Á9 mg/kg dose of intravenous TPA therapy within 3 h of symptom onset. All patients also had middle cerebral artery (MCA) occlusions on pretreatment TCD. They were randomized (1 : 1) to continuous TCD monitoring (Target) or placebo monitoring (control).
The safety end-point was symptomatic intracerebral hemorrhage (sICH) causing worsening of the neurological deficit by 4 or more NIHSS points. The primary combined activity end-point was complete recanalization on TCD or dramatic clinical recovery with a total NIHSS score r3 points, or improvement by Z10 NIHSS points within 2 h after TPA bolus. Clinical investigators were blinded to group assignment (active or sham monitoring) carried out by sonographers.
All projected 126 patients received TPA and were randomized 1 : 1 to target (median pre-treatment NIHSS 16 points) or control (NIHSS 17 points). Age, occlusion location on TCD, and time to TPA bolus were similar between groups. Symptomatic intracerebral hemorrhage occurred in 4Á8% of target patients and 4Á8% of controls. The primary end-point was achieved in 31 (49%, target) versus 19 (30%, control) patients, P 5 0Á03. At 3 months, 42% of target and 29% of control patients achieved favorable outcomes (mRS 0-1 points), NS. This trend shows the feasibility of a pivotal phase III clinical trial that, at 274 patients per group, would be properly powered to detect this difference in outcomes at 3 months (25).
Other clinical trials
Transcranial duplex technology was recently tested in a smaller randomized clinical trial (26) . Duplex transducers are different from those used in CLOTBUST since they generate multiple small beams at dual emitting frequencies, one for Doppler and one for gray-scale imaging (Fig. 1) . One of the major limitations of this technology is that there are no reliable head frames for transducer fixation, and most studies are carried out using a hand-held approach.
Eggers et al. (26) Fig. 1 Reported controlled clinical trials of ultrasound-enhanced systemic thrombolysis for acute ischemic stroke (25, 26, 32) . Abbreviations: n, total number of patients enrolled in both control and target groups; transducer, images of actual sources of ultrasound and their size relative to patient head; tissues exposed, images of beam paths as ultrasound propagates through the brain; sICH, percent rates of symptomatic intracranial hemorrhages; CR, complete recanalization at the end of the monitoring period; mRS 0-1, modified Rankin scores at 3 months followup (?, percent or actual number not reported in the original publication (32)). study did not have a predetermined sample size, and the results may be affected by a small number of patients enrolled. More studies are needed to evaluate the potential of transcranial duplex technology to enhance thrombolysis. The same group and others (27) (28) (29) reported provocative findings that patients who are not eligible for systemic TPA therapy may potentially benefit from continuous monitoring with ultrasound alone because, hypothetically, ultrasound may help facilitate the endogenous thrombolytic process that leads to spontaneous recanalizations in acute stroke patients. It is unclear if only partial recanalization can be induced by ultrasound alone, and if this exposure would result in a significant difference at 3 months, thus justifying a large clinical trial.
Furthermore, different experimental strategies are being tested in an extended time window for acute stroke treatment, and continuous exposure to ultrasound may find its application among patients who may be receiving other agents such as GP IIb-IIIa antagonists or direct thrombin inhibitors, or are awaiting intra-arterial procedures.
Ultrasound transducers were also incorporated into a catheter for intra-arterial delivery of a thrombolytic drug (EKOS Corporation). This intra-arterial device uses 1Á7-2Á1 MHz pulsed wave ultrasound with an emitting power of 400 mW, parameters similar to extracranially applied TCD. The EKOS catheter is now being tested in phase II-III Interventional Management of Stroke (IMS) trials (30) .
Therapeutic (i.e. non-imaging) ultrasound (31) has been tested in the TRanscranial low-frequency Ultrasound-Mediated thrombolysis in Brain Ischemia (TRUMBI) trial (32) . First, the investigators used a very low kilohertz system (o40 kHz) that produced intolerable tinnitus and was withdrawn from clinical testing (M Daffertshofer, unpublished data). It was replaced by a mid-kilohertz system operating at 300 kHz (Fig. 1) . The trial was terminated after 26 patients were enrolled with a 36% rate of symptomatic hemorrhage in the target group and no signal of efficacy on early recanalization or clinical outcomes at 3 months (32) . The trial demonstrated the bio-effects of mid-kilohertz ultrasound that promote bleeding, including brain areas not affected by ischemia (32) . Further research should determine if 'standing' pressure waves and endothelial disruption may cause these adverse effects. If confirmed in in vivo models, this will have implications on the design of future kilohertz-based systems.
Future directions
Ultrasound-enhanced thrombolysis can be further amplified by adding gaseous microbubbles (33) (34) (35) (36) . Microbubbles, safe ultrasound contrast agents, are micrometer-sized lipid shells that, when exposed to ultrasound, expand and produce stable cavitation with stronger reflected echoes. This is used to generate ultrasound images with better resolution. At the same time, microbubbles agitate fluid where they are released by ultrasound, and this is useful in drug delivery and mechanical 'grinding' of a thrombus. In fact, microbubbles have their own ability to lyse thrombi without a lytic drug (36) .
Several studies have been reported with different types of commercially available microbubbles (37) . Molina et al. (35) reported the largest study to date that compared the CLOT-BUST Target arm with the CLOTBUST target insonation protocol combined with Levovist air microbubbles (Schering AG, Germany). Investigators demonstrated that at 2 h after TPA bolus the TPA1TCD1Levovist group achieved a 55% sustained recanalization rate compared to 38% in the TPA1TCD group of the CLOTBUST trial. An international multicenter study of a new and more stable C 3 F 8 microbubble, MRX-815 nano-platform, is underway (38).
Microbubbles offer a mechanical way to amplify stroke therapies, and can be developed as a new kind of device to augment brain perfusion, and drug and nutrient delivery within the existing and at an extended time window. One problem in developing ultrasound and microbubble-assisted stroke therapies is the need of an experienced sonographer to find an intracranial thrombus, and expose its surface to residual flow in order to lodge more TPA and agitate stagnant flow. Personnel with these skills are lacking in most emergency centers. Future studies will focus on the development of an operator-independent ultrasound device that can be used by existing medical personnel regardless of their experience in diagnostic ultrasound.
